Asarina Pharma AB (publ) Q3 2020 report released
Asarina Pharma CEO Peter Nordkild: “During the third quarter 2020 we have been firmly focused on execution. We achieved full enrolment for our Phase IIa Menstrual Migraine study—despite tough Covid-19 restrictions, and continued preparations for our Phase IIa study in Tourette syndrome. We remain confident of completing both studies on schedule, so realizing our vision of bringing a new treatment modality to market for under-treated conditions that can help millions remain in control of their lives.”FINANCIAL HIGHLIGHTS · R&D costs at same level as in Q2, 2020 · Reduction in G&A and